Enzalutamide and sleep apnea: an emerging central nervous system side-effect?

Ann Oncol. 2016 Jan;27(1):206. doi: 10.1093/annonc/mdv481. Epub 2015 Oct 7.

Authors

F Labrize¹, L Cany², C Massard³, Y Loriot³, P Sargos⁴, M Gross-Goupil¹, G Roubaud⁵

Affiliations

¹ Department of Medical Oncology, Institut Bergonié, Bordeaux.
² Department of Medical Oncology, Clinique Francheville, Périgueux.
³ Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Sud, Villejuif.
⁴ Department of Radiotherapy, Institut Bergonié, Bordeaux, France.
⁵ Department of Medical Oncology, Institut Bergonié, Bordeaux [email protected].

PMID: 26445811
DOI: 10.1093/annonc/mdv481

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
Benzamides
Humans
Male
Nitriles
Phenylthiohydantoin / adverse effects
Phenylthiohydantoin / analogs & derivatives*
Phenylthiohydantoin / therapeutic use
Prostatic Neoplasms / drug therapy
Sleep Apnea Syndromes / chemically induced*

Substances

Antineoplastic Agents
Benzamides
Nitriles
Phenylthiohydantoin
enzalutamide